Gland Pharma Dundigal Facility Receives Four USFDA Form 483 Observations
Gland Pharma Ltd 路 Others (Uncategorized) 路 23 Oct 2026, 9:51 pm
Gland Pharma Dundigal Facility Receives Four USFDA Form 483 Observations The USFDA concluded an unannounced cGMP inspection at Gland Pharma Limited鈥檚 Dundigal formulation facility, conducted from 12th Oct'26 to 23rd Oct'26, issuing Form 483 with four observations. The company confirmed that all observations are procedural in nature, are neither repeated nor related to data integrity, and have no quantifiable impact on financials or operations. Corrective and preventive actions (CAPA) will be submitted to the regulator within the stipulated timeline.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation 路 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs 路 16 Nov 2026
- Grant of Options to Purchase Securities 路 16 Nov 2026
- Q2FY27 Earnings Call Transcript 路 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company 路 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 路 09 Nov 2026
- Q2FY27 Earnings Call Recording 路 07 Nov 2026
- Q2Fy27 Investors presentation 路 06 Nov 2026
